House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Cardiology

Hypertrophic cardiomyopathy: EJHF expert consensus

EJHF expert panel · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This 2026 EJHF expert consensus complements the ESC and AHA/ACC hypertrophic cardiomyopathy guidance with practical discussion of diagnosis, obstruction, myosin inhibitors, septal reduction and comorbidities. It is an expert statement rather than a newly graded comprehensive guideline. Management is organized around symptoms, haemodynamics and individualized risk, with explicit uncertainty in emerging treatments.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Define phenotype and investigate familial disease

  • Use echocardiography as first-line imaging and integrate clinical history, family history, multimodal imaging and genetic evaluation. In adults, unexplained LV wall thickness ≥15 mm is the main imaging criterion; exclude hypertension, valve disease and phenocopies rather than diagnosing HCM from thickness alone. [1]
  • Assess resting and physiologically provoked LV outflow gradients. A gradient ≥30 mmHg defines obstructive HCM in this statement; symptoms and haemodynamic context, rather than this definition alone, determine treatment. [1]
  • Screen first-degree relatives with ECG and echocardiography. Consider genetic testing in confirmed HCM, particularly familial, early-onset or syndromic presentations, with attention to diseases that mimic sarcomeric HCM. [1]
  • Use ambulatory ECG monitoring to detect atrial fibrillation and nonsustained ventricular tachycardia. The consensus regards annual 24-hour Holter monitoring as reasonable without known arrhythmia, with more frequent or extended monitoring for higher-risk patients or concerning symptoms. [1]

Treat obstruction with safety monitoring

  • Beta-blockers are first-line symptomatic therapy, particularly with LV outflow obstruction. The statement favors beta-one-selective agents; tailor treatment to symptoms, heart rate, blood pressure and comorbidities rather than pursuing gradient reduction at the expense of bradycardia. [1]
  • Verapamil or diltiazem can relieve symptoms when beta-blockers are not tolerated. Use particular caution with verapamil in markedly elevated LV outflow gradients, severe pulmonary hypertension or baseline systemic hypotension because haemodynamic deterioration can occur. [1]
  • Disopyramide may be added for persistent obstruction and symptoms despite beta-blocker or calcium-channel-blocker therapy. Monitor QTc during titration and renal function, and account for anticholinergic adverse effects and availability. [1]
  • Myosin-inhibitor treatment for symptomatic obstructive HCM requires serial echocardiographic assessment of systolic function and careful drug-interaction review. The consensus emphasizes early monitoring and an integrated response assessment including symptoms and exercise tolerance, rather than gradient alone. [1]
  • Temporarily withhold mavacamten if LVEF falls below 50%. Reinitiation at a lower dose after recovery and recurrence of obstruction requires specialist reassessment; the excerpt does not provide a complete dosing algorithm. [1]
  • Do not extrapolate obstructive-HCM myosin-inhibitor benefits to routine nonobstructive treatment. The paper reports that the nonobstructive ODYSSEY-HCM trial missed its functional and quality-of-life endpoints and describes further agents as investigational. [1]

Individualize procedural and arrhythmic risk decisions

  • For obstructive HCM with persistent symptoms despite optimized medication, consider septal reduction through a multidisciplinary expert HCM team. Choose surgical myectomy or alcohol ablation using anatomy, comorbidities, patient preference and centre expertise. [1]
  • Prefer myectomy when associated mitral or subvalvular abnormalities need correction or coronary bypass is required. Alcohol septal ablation needs suitable septal anatomy and carries a risk of conduction block requiring pacing. [1]
  • Use established sudden-death risk assessment as a starting point and integrate clinical judgement, imaging and shared decision-making. Extensive late gadolinium enhancement is a risk modifier, but technical variability limits treating a single fibrosis cutoff as a universal ICD rule. [1]
  • Asymptomatic obstructive HCM generally calls for structured surveillance and objective assessment of exercise limitation, rather than routine medication or septal reduction solely for a high gradient. Reassess when clinical status changes. [1]

Address comorbidity and family surveillance

  • In HCM with atrial fibrillation, the consensus recommends anticoagulation regardless of CHA2DS2-VASc score, with DOACs favored. Choose rate and rhythm treatment in the context of obstruction; atrial enlargement without documented AF is not an automatic anticoagulation indication. [1]
  • Treat blood pressure with attention to obstruction: beta-blockers or nondihydropyridine calcium-channel blockers are preferred initial agents in obstructive HCM. Use afterload-reducing agents and diuretics cautiously because hypotension or volume depletion can worsen outflow obstruction. [1]
  • For genotype-positive, phenotype-negative individuals, the consensus supports individualized ECG and echocardiographic surveillance, generally at intervals of 1–3 years. Adjust frequency to age, familial penetrance and clinical circumstances. [1]
  • Encourage moderate recreational exercise for low-risk HCM patients unless specific clinical factors contraindicate it. High-intensity or competitive sport needs individualized shared decision-making that weighs disease features and individual circumstances. [1]

Limitations and use

  • This selected consensus summary is not a complete prescribing, ICD-eligibility or procedural protocol. Drug licensing, interactions and monitoring schedules require the current product information and specialist guidance. The paper mixes established care with emerging evidence, including extrapolated heart-failure treatment and ongoing trials; these are not equivalent to confirmed HCM-specific benefit. Detailed pregnancy, paediatric and genetic-variant decisions require specialist assessment.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Hypertrophic cardiomyopathy: EJHF expert consensus

    Selected recommendation material consulted

Expert consensus

Publication details

Issuing organisation
EJHF expert panel
Resource type
Expert consensus · House clinical summary

Earlier House summaries: hypertrophic cardiomyopathy esc

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Define phenotype and investigate familial disease
  • Treat obstruction with safety monitoring
  • Individualize procedural and arrhythmic risk decisions
  • Address comorbidity and family surveillance
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House